Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values

Pharmaceutical Research

Volumn 29, Issue 3, 2012, Pages 651-668

  Tachibana, Tatsuhiko ^a   Kato, Motohiro ^a   Sugiyama, Yuichi ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

CYP3A4; Human; Intestine; Nonlinear absorption; P gp

Indexed keywords

COLCHICINE; CYTOCHROME P450 3A4; DIAZEPAM; FELODIPINE; GLYCOPROTEIN P; LEVOFLOXACIN; NITRENDIPINE; OXYBUTYNIN; PRAZOSIN; RISPERIDONE; RITONAVIR; CYTOCHROME P450 3A; DRUG;

AREA UNDER THE CURVE; ARTICLE; CALCULATION; DECISION TREE; DRUG ABSORPTION; DRUG CLEARANCE; IN VITRO STUDY; INTESTINE ABSORPTION; MATHEMATICAL COMPUTING; MAXIMUM PLASMA CONCENTRATION; MICHAELIS CONSTANT; NONLINEAR SYSTEM; PREDICTION; PRIORITY JOURNAL; BIOLOGICAL MODEL; HUMAN; METABOLISM; PHARMACOKINETICS;

AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DECISION TREES; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; P-GLYCOPROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84862321296     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0579-2     Document Type: Article

References (41)

1. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 "pie". Drug Metab Dispos. 2006;34(5):880-6.
2. Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, et al. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet. 2003;18(6):365-72.
3. Kato M, Chiba K, Ito T, Koue T, Sugiyama Y. Prediction of interindividual variability in pharmacokinetics for CYP3A4 sub-strates in humans. Drug Metab Pharmacokinet. 2010;25(4):367-78.
4. Kadono K, Akabane T, Tabata K, Gato K, Terashita S, Teramura T. Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. Drug Metab Dispos. 2010;38(7):1230-7.
5. Varma MV, Sateesh K, Panchagnula R. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm. 2005;2(1):12-21.
6. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995;13(3):129-34.
7. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm. 2004;277(1-2):3-9.
8. Cummins CL, Jacobsen W, Christians U, Benet LZ. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther. 2004;308(1):143-55.
9. Gertz M, Harrison A, Houston JB, Galetin A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos. 2010;38(7):1147-58.
10. Rostami-Hodjegan A, Tucker GT. 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interaction. Drug Discovery Today: Tech. 2004;1(4):441-8.
11. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab. 2007;8(7):676-84.
12. Tachibana T, Kato M, Takano J, Sugiyama Y. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. Curr Drug Metab. 2010;11(9):762-77.
13. Tachibana T, Kato M, Watanabe T, Mitsui T, Sugiyama Y. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica. 2009;39(6):430-43.
14. Boyd RA, Lalonde RL. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? Clin Pharmacol Ther. 2007;81(1):24-6.
15. Wagner CC. Langer O. Adv Drug Deliv Rev: Approaches using molecular imaging technology - use of PET in clinical microdose studies; 2010.
16. Lewis LD. Early human studies of investigational agents: dose or microdose? Br J Clin Pharmacol. 2009;67(3):277-9.
17. Combes RD, Berridge T, Connelly J, Eve MD,Garner RC, Toon S, et al. Early microdose drug studies in human volunteers can minimise animal testing: proceedings of a workshop organised by Volunteers in Research and Testing. Eur J Pharm Sci. 2003;19(1):1-11.
18. Wang JL, Aston K, Limburg D, Ludwig C, Hallinan AE, Koszyk F, et al. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: the three microdose candidates. Bioorg Med Chem Lett. 2010;20(23):7164-8.
19. Zhou XJ, Garner RC, Nicholson S, Kissling CJ, Mayers D. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects. J Clin Pharmacol. 2009;49(12):1408-16.
20. Madan A, O'Brien Z, Wen J, O'Brien C, Farber RH, Beaton G, et al. A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol. 2009;67(3):288-98.
21. Ozawa N, Shimizu T, Morita R, Yokono Y, Ochiai T, Munesada K, et al. Transporter database, TP-Search: a web-accessible comprehensive database for research in pharmacokinetics of drugs. Pharm Res. 2004;21(11):2133-4.
22. Uchimura T, Kato M, Saito T, Kinoshita H. Prediction of human blood-to-plasma drug concentration ratio. Biopharm Drug Dispos. 2010;31(5-6):286-97.
23. Lilja JJ, Kivisto KT, Backman JT, Lamberg TS, Neuvonen PJ. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther. 1998;64(6):655-60.
24. Milne RJ, Buckley MM. Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease. Drugs. 1991;41(6):941-69.
25. Lilja JJ, Backman JT, Laitila J, Luurila H,Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther. 2003;73(3):192-8.
26. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001;18(2):171-6.
27. Korjamo T, Kemilainen H, Heikkinen AT, Monkkonen J. Decrease in intracellular concentration causes the shift in Km value of efflux pump substrates. Drug Metab Dispos. 2007;35(9):1574-9.
28. Shirasaka Y, Sakane T, Yamashita S. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci. 2008;97(1):553-65.
29. Tachibana T, Kitamura S, Kato M, Mitsui T, Shirasaka Y, Yamashita S, et al. Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res. 2010;27(3):442-6.
30. Heikkinen AT, Korjamo T, Lepikko V, Monkkonen J. Effects of experimental setup on the apparent concentration dependency of active efflux transport in in vitro cell permeation experiments. Mol Pharm. 2010;7(2):605-17.
31. Kato Y, Miyazaki T, Kano T, Sugiura T, Kubo Y, Tsuji A. Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009;98(7):2529-39.
32. Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, Tamai I. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther. 2010;332(1):181-9.
33. Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother. 1998;42(2):332-8.
34. Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol. 2004;57(4):473-86.
35. Iwatsubo T, Hisaka A, Suzuki H, Sugiyama Y. Prediction of in vivo nonlinear first-pass hepatic metabolism of YM796 from in vitro metabolic data. J Pharmacol Exp Ther. 1998;286(1):122-7.
36. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 1999;27(11):1350-9.
37. Yamane N, Tozuka Z, Sugiyama Y, Tanimoto T, Yamazaki A, Kumagai Y. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;858(1-2):118-28.
38. Yamazaki A, Kumagai Y, Yamane N, Tozuka Z, Sugiyama Y, Fujita T, et al. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS. J Clin Pharm Ther. 2010;35(2):169-75.
39. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, et al. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci. 2010;40(2):125-31.
40. Bolger MB, Lukacova V, Woltosz WS. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J. 2009;11(2):353-63.
41. Tubic M, Wagner D, Spahn-Langguth H, Bolger MB, Langguth P. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm Res. 2006;23(8):1712-20.